+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
ID06734702

Study of Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Chemoradiotherapy and Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer

Led by Sun Yat-sen University · Updated on 2025-07-24

497

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the best timing and combination of treatments for patients with locally advanced non-small cell lung cancer LANSCLC, focusing on neoadjuvant immuno-chemotherapy combined with chemoradiotherapy and consolidative immunotherapy. This phase III randomized controlled trial compares the effectiveness and safety of adding neoadjuvant immuno-chemotherapy before concurrent chemoradiotherapy and consolidative immunotherapy, versus chemoradiotherapy and consolidative immunotherapy alone. The study builds on previous findings from the PACIFIC trial that established immunotherapy after chemoradiotherapy as a standard care, aiming to improve survival outcomes further. Participants are randomly assigned into three groups. Group A receives neoadjuvant chemo-immunotherapy with albumin-bound paclitaxel, cisplatin, and tislelizumab every three weeks, followed by hypofractionated thoracic radiotherapy hypo-RT with concurrent chemotherapy, then consolidative immunotherapy for up to 12 months. Group B undergoes the same neoadjuvant chemo-immunotherapy but with conventionally fractionated thoracic radiotherapy CFRT and concurrent chemotherapy, followed by consolidative immunotherapy for up to 12 months. Group C receives CFRT with concurrent chemotherapy first, then consolidative immunotherapy for up to 12 months. During the trial, participants will have regular assessments including tumor response evaluations, survival tracking, and safety monitoring for adverse events. Quality of life will be measured using specific questionnaires at one year after treatment. Researchers will also monitor eligibility for consolidative immunotherapy following chemoradiotherapy. The primary outcome is progression-free survival at 18 months, with additional follow-ups for overall survival and treatment safety planned over two years. The total participation duration may extend up to several years, including long-term monitoring.

CONDITIONS

Brief Title

Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Research Team

B

Bo Qiu, Professor

H

Hui Liu, Professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here